Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Apr 14, 2009; 15(14): 1771-1773
Published online Apr 14, 2009. doi: 10.3748/wjg.15.1771
Published online Apr 14, 2009. doi: 10.3748/wjg.15.1771
Table 1 Laboratory test results by treatment regimen
| Azathioprine | Cyclosporine | Infliximab (after 18 mo of treatment) | |
| Hemoglobin, g/dL | 5.0 | 8.0 | 13.0 |
| Hematocrit (%) | 13 | 19 | 40 |
| Erythrocyte sedimentation rate, mm in the first hour | 130 | 230 | 7 |
| Albumin, g/dL | 2 | 2.5 | 3.5 |
| Iron, mg/dL | 10 | 15 | 55 |
| α-1 glycoprotein, mg/dL | 230 | 245 | < 100 |
| C-reactive protein, mg/dL | > 5 | > 5 | < 5 |
Table 2 Mayo scale score for ulcerative colitis by treatment regimen
| Azathioprine | Cyclosporine | Infliximab | |
| Frequency of evacuations | 3 | 3 | 0 |
| Rectal bleeding | 3 | 3 | 0 |
| Endoscopic findings | 3 | 3 | 0 |
| Overall medical evaluation | 3 | 3 | 0 |
- Citation: Cury DB, Cury MS, Elias GVH, Mizsputen SJ. Infliximab to treat severe ulcerative colitis. World J Gastroenterol 2009; 15(14): 1771-1773
- URL: https://www.wjgnet.com/1007-9327/full/v15/i14/1771.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.1771
